Device Trial Radar · NCT04785560
Volumetrics and Proteomics in Shunted Normal Pressure Hydrocephalus
Last checked: Nov 20, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
58
Actual
Start
Mar 8, 2021
Primary completion
Jul 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- University Hospital, LinkoepingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 8, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Idiopathic normal pressure hydrocephalus (=iNPH) is a condition with disturbed circulation of cerebrospinal fluid (=CSF) causing symptoms such as balance and gait disorders, urinary incontinence and cognitive impairment in patients with cerebral ventricular dilation. The exact incidence is unknown but has been estimated at about 8.9% of the population over the age of 80 and the incidence is estimated to increase with an aging population. The symptoms can be temporarily improved by draining cerebrospinal fluid and so-called shunting (surgery with diversion of cerebrospinal fluid from the brain to the abdominal cavity). The symptoms and pathophysiology of iNPH are poorly described as well as the protein distribution in cerebrospinal fluid (proteomics) of the disease. There is also a need for improved diagnostical and prognostical tools that can guide in patient selection for surgery. The radiological tools in evaluating the disease and it´s progression need to be improved. There is a shunt valve (Codman Certas Plus) used since 2015 that is widely used in clinical use and is well studied in research laboratories but little in clinical studies. The project aims to, before and after surgery, on patients with iNPH who will undergo investigation and shunting with Certas Plus at our department and in comparison with healthy controls: 1. Apply and evaluate a novel method to determine the volume of circulating CSF (volumetry). 2. Study the correlation between changes in volumetry and clinical outcome 3. Study NPH patients' distribution of proteins in cerebrospinal fluid and their change over time after shunting. 4. Evaluate the efficacy and functions of the Certas Plus valve. In this way, the investigators hope to find increased knowledge about the NPH disease and its pathophysiology as well as useful instruments that can both predict the probability for a patient to be improved by a shunt operation and determine if a shunt has stopped working and thus be able to avoid unnecessary risky operations.
Conditions
- Hydrocephalus, Normal Pressure
- Ventriculomegaly, Cerebral
- Shunt; Complications
- Hydrocephalus Acquired
Interventions
Initial shunt setting post-operatively of the Certas Plus shunt valve.Device
The setting/resistance of the Certas Plus Shunt valve implanted is set according to randomisation and is not changed until the first post-operative MRI is performed 36-48 hours after surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Idiopathic normal pressure hydrocephalus scaleTime frame: Assessed within 3 months pre-operatively and 3 months post-operatively.
- Change from baseline CSF volume at 2 days postoperatively.Time frame: Assessed on MRI scan 36-48 hours post-operatively.
- Change from baseline CSF volume at 3 months post-operatively.Time frame: Assessed on MRI scan 3 months post-operatively
6 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neurosurgical department University Hospital Linköping
Linköping, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.